Astellas took an exclusive option to license a preclinical immuno-oncology asset targeting IL-12 from Audax Biosciences. The structure includes $285 million tied to an upfront component and subsequent payments based on development milestones. The agreement underscores continued pharma willingness to fund early immunotherapy programs, particularly where cytokine biology may unlock new combinations or differentiation. For Audax, the option adds financial runway while transferring downstream development decision points to Astellas. Strategically, IL-12 remains a biologic target with historical clinical complexity; the deal signals that Astellas sees enough promise in the specific preclinical program to justify milestone-linked investment.